Theratechnologies (TSE:TH) Sets New 12-Month High - Still a Buy?

Key Points

• Theratechnologies reached a new 52-week high of C$4.66 during trading, with a trading volume of 65,161 shares.
• Jones Trading downgraded the stock rating from a "strong-buy" to a "hold," leading to a consensus rating of "Buy" from analysts.
• The company has a market capitalization of C$215.65 million and offers products that address the medical needs of HIV patients in Canada and the U.S.

Theratechnologies Inc. (TSE:TH - Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as C$4.66 and last traded at C$4.66, with a volume of 65161 shares traded. The stock had previously closed at C$4.58.

Wall Street Analyst Weigh In

Separately, Jones Trading lowered shares of Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy".

Theratechnologies Stock Performance

The company has a 50-day moving average price of C$4.44 and a two-hundred day moving average price of C$3.67. The stock has a market capitalization of C$215.65 million, a P/E ratio of -24.68, a PEG ratio of -8.50 and a beta of 0.26. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of -293.92.

About Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.